Precision Antimicrobial STewardship for Clostridioides DIfficile Prevention
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13,319
- 试验地点
- 1
- 主要终点
- Per-Admission Rate
研究概览
简要总结
To decrease CDI incidence by implementing an electronic health record-integrated CDI-risk classification tool for Clostridioides difficile infection (CDI) to focus a bundle of antimicrobial stewardship (AMS) CDI prevention recommendations on high-risk patients.
详细描述
This study aims to use a pre/post implementation design to evaluate the use of a novel risk classification tool to improve existing methods of identifying patients eligible for routine antimicrobial stewardship (AMS) care processes targeting reduction of Clostridioides difficile infection (CDI). Antimicrobial stewardship is an established, evidence-based quality improvement program that is required by The Joint Commission and a condition of participation by the Centers for Medicare and Medicaid. AMS processes of care are evidence based, supported by published research demonstrating outcomes benefits, are recommended by national guidelines and are not investigational. Treatment decisions remain at the discretion of clinicians and patients
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •adult acute care patients identified as high-CDI risk by the CDI risk classification tool. This sub-group represents approximately 6% of all acute care admissions
排除标准
- •Behavioral health units
- •Inpatient rehabilitation units
- •Labor and Delivery units
- •Same day surgery and observation units
结局指标
主要结局
Per-Admission Rate
时间窗: 30 days after discharge
per-admission rate of hospital-associated CDI, defined as: positive toxin B by enzyme-linked immunoassay or polymerase chain reaction test at least 72 hours after admission
次要结局
- Total Antibiotic Usage(through study completion, an average of 1 year)
- Hospital Length of Stay(through study completion, an average of 1 year)
- High-Risk Antibiotic Usage(through study completion, an average of 1 year)
- Proton Pump Inhibitor Therapy Administered(through study completion, an average of 1 year)
- Total Variable Cost per Admission(through study completion, an average of 1 year)